NASDAQ · Biotechnology

Propanc Biopharma, Inc. (PPCB) Stock

$0.47 -5.55% NASDAQ: PPCB Healthcare

Valuation

MetricValue
Price$0.47
Market Cap$1.07M
P/E Ratio-0.02
P/B Ratio0.18
P/S Ratio47.73
EPS (TTM)$-371.25
52-Week High$52.50
52-Week Low$0.46
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-167.51%
ROA-147.60%
ROCE-192.94%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.05
Current Ratio1.33

Annual Financials (USD)

Metric20222023202420252026
Revenue$0$0$0$0$0
Operating Profit$-2.0M$-2.0M$-2.0M$-57.0M$-18.0M
Net Profit$-3.0M$-3.0M$-2.0M$-59.0M$-19.0M
EPS$-27986891.75$-781709.75$-30000.00$-371.25$-17.62
Op Margin—————

Balance Sheet (USD)

Metric20222023202420252026
Total Assets$0$0$0$20.0M$13.0M
Total Liabilities$3.0M$3.0M$4.0M$6.0M$3.0M
Cash$0$0$0$0$1.0M
Borrowings$1.0M$1.0M$1.0M$2.0M$0

Latest News

Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal GlobeNewswire · Jul 21, 2026 Propanc Biopharma Signs MoU With Avance Clinical to Jointly Undertake Advanced Solid Tumors Study MT Newswires · Jul 7, 2026 Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd GlobeNewswire · Jul 7, 2026 Propanc Biopharma Launches $5 Million Stock Buyback Plan; Shares Rise MT Newswires · Jul 2, 2026 Propanc Biopharma Initiates $5.0 Million Share Repurchase Program GlobeNewswire · Jul 2, 2026

Cash Flow (USD)

Metric20222023202420252026
Operating Cash Flow$-1.0M$-1.0M$-1.0M$0$-6.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$1.0M$0$1.0M$0$1.0M
Net Cash Flow$0$0$0$0$1.0M
Free Cash Flow$-1.0M$-1.0M$-1.0M$0$-6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.05
FCF Yield-500.60%
Quick Ratio2.55
Interest Coverage-42.24
Return 1Y-98.67%
Return 3Y-65.47%
Return 5Y-99.93%

Ownership

Insiders Held45.13%
Institutions Held0.81%
Institutions Float Held1.48%
Institutional HolderSharesReport Date
UBS Group AG7,3052026-03-31
Jane Street Group, LLC5,7292026-03-31
Marex Group Plc2,7092026-03-31
Virtu Financial LLC1,6302026-03-31
Sassicaia Capital Advisers, LLC6402026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CLCSCell Source, Inc. $0.80 -6.98% -8.00 $36.03M 0.00%
GLABFGemina Laboratories Ltd. $0.05 +0.00% -1.54 $3.83M 0.00%
HOOKHOOKIPA Pharma Inc. $1.15 +0.00% -0.71 $14.40M 0.00%
IMUCEOM Pharmaceuticals Holdings, Inc. $0.25 +90.77% -16.32 $31.37M 0.00%
PRVCFPreveCeutical Medical Inc. $0.01 +12.00% -5.00 $8.37M 0.00%

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. is led by CEO James Nathanielsz, employs 1 people, headquartered in AU, publicly traded since 2012.

Propanc Biopharma, Inc. (PPCB) stock trades at $0.47 with a market capitalization of $1.07M. The stock is valued at a price-to-earnings (P/E) ratio of -0.02, price-to-book of 0.18, price-to-sales of 47.73. Over the past 52 weeks the stock has ranged between $0.46 and $52.50, and currently trades 99.1% below its 52-week high.

On profitability, Propanc Biopharma, Inc. generates a return on equity (ROE) of -167.51%, return on capital employed of -192.94%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1169.93 -1.58% JNJ Johnson & Johnson $256.48 -0.76% ABBV AbbVie Inc. $272.42 +0.39% MRK Merck & Company, Inc. Common Stock (new) $142.40 -0.28% UNH UnitedHealth Group Incorporated Common Stock (DE) $370.95 -1.34% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $158.78 -0.84% TMO Thermo Fisher Scientific Inc $651.98 -1.52% AMGN Amgen Inc. $407.44 -1.37% GILD Gilead Sciences, Inc. $147.10 +0.17% ABT Abbott Laboratories $98.49 -0.24% NVO Novo Nordisk A/S $38.18 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides